These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16990641)

  • 1. Current status of the prevention of cytomegalovirus disease in solid organ transplant recipients. Introduction.
    Baillie GM
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S2. PubMed ID: 16990641
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention and treatment of cytomegalovirus disease in solid organ transplant recipients: the clinical and economic impact of evolving strategies. Introduction.
    Pescovitz MD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S3-4. PubMed ID: 14686227
    [No Abstract]   [Full Text] [Related]  

  • 3. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of cytomegalovirus infection in solid-organ transplant recipients.
    Murray BM
    Immunol Invest; 1997; 26(1-2):243-55. PubMed ID: 9037627
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
    Kowalsky S; Arnon R; Posada R
    Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.
    Singh N
    Clin Infect Dis; 2005 Mar; 40(5):704-8. PubMed ID: 15714416
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus disease in transplant recipients.
    Faoagali JL
    N Z Med J; 1994 Jan; 107(970):18. PubMed ID: 8295749
    [No Abstract]   [Full Text] [Related]  

  • 10. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis.
    Snydman DR
    Clin Infect Dis; 2005 Mar; 40(5):709-12. PubMed ID: 15714417
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
    Koval CE
    Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
    Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
    Paya CV
    Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prevention of cytomegalovirus infection and disease by administration of biological products].
    Ihara T
    Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cytomegalovirus disease.
    Bailey TC
    Semin Respir Infect; 1993 Sep; 8(3):225-32. PubMed ID: 8016483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.